In another study, Kramer et al. demonstrated in their phase I study that compartmental radioimmunotherapy (cRIT) combined with the anti-B7-H3 murine monoclonal antibody omburtamab could be a promising strategy for NB treatment [108]. The gene discussed is CD276; the disease is neuroblastoma.